New surgery combo for pancreatic cancer aims to cut complications and speed recovery
NCT ID NCT05843877
First seen Feb 01, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This study compares two surgical approaches for people with pancreatic cancer who are at high risk for a serious complication called a pancreatic fistula. One group gets the standard surgery that removes only the tumor-affected part of the pancreas. The other group has the entire pancreas removed and receives a transplant of their own insulin-making cells (islets) into the liver. The goal is to see if the more extensive surgery reduces complications and helps patients start additional cancer treatments faster.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIAMPULLARY CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Carl Gustav Carus Technische Universität Dresden
RECRUITINGDresden, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
autologous pancreatic islet cells
What this could lead to
If successful, this approach could reduce serious complications after pancreatic cancer surgery and help patients start additional cancer treatments sooner.
What could go wrong
This is a small early-phase trial with only 32 participants, so results may not apply to all patients. The islet transplant may not produce enough insulin, and patients will still need close monitoring.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.